

Index

a

- absorption, distribution, metabolism, and excretion (ADME) screening
 - and pharmacokinetics 245
 - protein binding 244
 - QSAR approaches 246
 - *in silico* approaches 245, 246
 - space, concept of 233–235
 - and transporters 242–244
- absorption process 42
 - absorption potential
 - boundaries of 50
 - estimation, model for 56, 57
 - absorption window 45
 - paracellular 45
 - drugs absorbed by 46
 - and renal clearance, correlation between 109
 - proportion absorbed, calculation 45
 - rate of absorption (k_a) 26, 45
 - rate of disappearance 45
 - solubility-limited 12
- active transport 55
 - mechanism 12
- acyl glucuronides 172
- β -adrenoceptor antagonists
 - to cause sleep disorders 68
 - central receptor occupancy
 - after oral administration of 69
 - elimination rate constant
 - for *in vitro* metabolism against lipophilicity 96
 - lipophilicity ($\log D_{7.4}$) 32
 - with unbound (free) hepatic intrinsic clearance and 96
 - with unbound (free) volume of distribution ($V_{d(u)}$) 95
 - with *in vitro* potency (P_{A_2}) for 93, 94
 - physicochemical characteristics 51
 - agranulocytosis 174
 - aldehyde oxidase-catalyzed reactions
 - activation of antiviral prodrug famciclovir 130
 - inotropic agent carbazeran, metabolism of 128
 - oxidation, of azetidinyll ketolide derivatives 129
 - p38 inhibitor RO1, metabolism of 129
 - SB-277011, a dopamine antagonist, substrate for 128
 - zaleplon, substrate for 127
 - aliskiren 14, 46, 54
 - allometric scaling 213
 - clearance, allometric relationship 216
 - allometry plus fraction-corrected intercept method 220, 221
 - allometry plus rule of exponents 219, 220
 - brain weight 220
 - maximum life span potential 220
 - metabolic clearance 218
 - renal clearance 217
 - rule of exponents 220
 - single-species scaling, with fixed scaling factor 222
 - traditional allometry 217
 - transporter-mediated clearance 218, 219
 - of preclinical *in vivo* pharmacokinetic parameters 213
 - volume of distribution, methods for 213–216
 - amodiaquine 172, 173
 - amphiphilic drugs 11
 - antidepressants, CYP3A4 clearances of 125, 126
 - antifungal agents 100, 197, 214
 - azole 196, 197

- nitrogen-containing heterocycles, essential in 196
 - structures of 110
 - antihistamine compounds, penetration into CNS 64
 - correlated with $\Delta \log P$ 64
 - aqueous channels 33
 - aromatic hydroxylation
 - fenclofenac, resistant to 119
 - function more amenable to 122
 - metabolism, SCH 48461 occur by 138
 - performed by the cytochrome P450 system 113
 - aryl hydrocarbon receptor (AhR) 186
 - N-arylsulfonamide-based γ -secretase inhibitors 125
 - improving metabolic stability through 125
 - reducing oxidative clearance 125
- b**
- betaxolol 50
 - bioactivation
 - acetaminophen 186
 - of antiinflammatory agent acetaminophen to 166
 - of clopidogrel into a pharmacologically reactive metabolite 174
 - *de novo*, of 4-fluoro-N-methylaniline, role of FMO 131
 - of 4-fluoro-N-methylaniline 131
 - of lead compound associated with 172
 - metabolic pathways of paroxetine and raloxifene 182
 - nefazodone bioactivation pathway 168
 - for reactive metabolite formation, and subsequent implementation 195
 - and toxicity related to UGT-dependent metabolism 145
 - bioavailabilities 46
 - biomembranes 14, 44
 - Biopharmaceutics Classification System (BCS) 13
 - categories 13
 - and central role of permeability 13–15
 - PSA/log P , relationship 14
 - blood–brain barrier (BBB) 8, 63, 64
 - brain/blood partitioning 65
 - brain penetration 63–66
 - accumulation of lower permeability compounds 67, 68
 - brain/blood partitioning 65
 - distribution of drugs, into tumors 68–70
 - free unbound drug partitioning 65
 - influx and efflux proteins 64
 - lipophilicity of compounds 65
 - and CNS penetration, relationship 66
 - major transport proteins 63
 - penetration of antihistamine compounds 64, 65
 - permeability 63
 - role of H bonding potential 63, 64
 - use of microdialysis 65
 - volume of distribution, of drug molecule 70
 - and duration 70–77
 - and T_{\max} 77, 78
 - breast cancer resistance protein 69
- c**
- Caco-2 assay 243
 - calcium channel antagonists 93
 - calcium channel blockers
 - dihydropyridine 73
 - primary amine containing 22
 - rapidly metabolized drugs 123
 - with high Cl_i values 27
 - camptothecins, distribution into tumor 69
 - carfentanil 38
 - catechol-O-methyl transferase (COMT) inhibitors 148, 182
 - cellular membrane 12
 - chloroform 10
 - chloroquine 12, 173
 - chlorphentermine 11
 - cholesterol absorption inhibitors 138
 - computational toxicology 183, 184
 - covalent modifications
 - drugs inactivating CYP enzymes through 194
 - irreversible CYP inactivation via apoprotein 193–195
 - cromakalim, steps in the discovery of 139
 - crystallization 43, 44
 - cyclic peptides 7
 - cyclohexane 6
 - cyclosporine A (CsA) 7, 49, 119, 120, 190
 - cytochrome P450 (CYP) system 112
 - cycle, key stages of substrate interaction 113, 114
 - CYP1A2 84, 97, 114, 198
 - affinities for 199
 - inhibition 201, 202
 - CYP3A4 84, 98, 114, 168, 169, 173, 180, 182, 183, 186–188, 190, 242
 - catalytic selectivity of 119–126
 - clinical toxicities, and side effects 189
 - concentrations for 189
 - inducers 187
 - induction 188

- inhibition 200, 201
- inhibitor 198
- CYP2C9 84, 114, 115
- catalytic selectivity of 117–119
- inhibition 201, 202
- CYP2C19 84, 114, 173, 174
- inhibition 201, 202
- CYP2C8, inactivation by gemfibrozil 195
- CYP2D6 39, 84, 97, 114, 182, 193
- catalytic selectivity of 115–117
- gene, highly polymorphic 118
- CYP2E1 114, 115, 186
- forms of CYPs, involved in metabolism of 114, 115
- heteroatom oxidation of drugs by 113
- monooxygenase 112, 113
- reactions performed by 113

d

- detoxication
 - of electrophilic quinone metabolites, role of COMT in 147
 - GSTs, role in 149
 - pathways in attenuating covalent binding to hepatic tissue 182
- diltiazem
 - benzozapepinone analogue 124
 - extensively metabolized drug 123
- dissociation constant (K_a) 4
- dissolution. *See also* solubility
 - depends on surface area of 42
 - dissolution-limited drugs 43
 - formulations 42
 - general solubility ($\log S$) equation for 42
 - incorporation of ionizable center 43
 - Ostwald's rule of stages 44
 - rate, affected by 42
- distribution coefficient (D) 2–4
 - for monoprotic acid (HA) 4
- dopamine D3 receptor antagonists 198
- drug clearance
 - active metabolites 88–91
 - clearance processes 82, 83
 - intravenous administration 22–24
 - renal and metabolic clearance
 - interplay between 83–86
 - and potency, balancing rate of 91–101
 - propranolol vs. atenolol 98
 - role of
 - lipophilicity in 87, 88
 - transport proteins in 83–86
- drug conjugation, enzymes catalyzing 144
 - conjugation processes, stability to 149–152

- glucuronosyl transferases 144–147
- mechanism of glucuronidation reactions 145
- reactions performed by 144
- glutathione-s-transferases 148, 149
- methyl transferases 147, 148
- pharmacodynamics and 152, 153
- sulfotransferases 144–147
- drug design 138
 - advancement of automation 232
 - enzyme induction and 186–191
 - enzyme inhibition and 191
 - reactive metabolite positives, in risk assessment strategies 173, 179–181
- competing detoxication pathways 182, 183
- effect of daily dose 173, 179–181
- structural alerts/toxicophores in 173
- drug distribution 62, 72. *See also* volume of distribution (V_d)
 - alveolar macrophages reflecting ionized basic 76
- drug–drug interactions 242, 243
- drug-like properties 9
- drug metabolism 112. *See also* lipophilicity
 - AO-mediated 126, 127
 - automation of assays for 233
 - and discovery screening sequences 235, 236
 - enzymes of 49
 - involvement of MAO in 137
 - phase I and phase II processes 112
 - theoretical models for predicting 246, 247
- drug partitioning, free unbound 65

e

- entacapone 147, 148
- enzyme inhibition 191
 - CYP inhibition by nitrogen-containing heterocycles 195–199, 203
 - irreversible CYP inactivation via apoprotein and 193–195
 - MI complex formation 192, 193
 - quasi-irreversible inhibition 191–193
- esterases, nonspecific 138
- ester drugs, as intravenous and topical agents 140–142
- function 138–140

f

- FAD C-4 α -hydroperoxy form of FMO enzymes 131
- flavin monooxygenases 241

g

- genomics 234
- Gibbs free energy 44
- glucuronidation 86, 112, 144–146, 150–152, 173, 241
 - activity catalyzed by uridine 5'-diphosphoglucuronosyltransferase 241
 - mechanism 145
 - phenol-containing VEGF-2 receptor kinase inhibitors, reducing liability of 150
 - of 6-position to form morphine-6-glucuronide 152
 - rates of *N*-hydroxyurea-based 5-lipoxygenase inhibitors 151
- glucuronosyl transferases 144–147
- glutathione-s-transferases 148, 149
- G-protein-coupled receptors 34, 62

h

- half-life 21, 23, 25, 39, 72, 74, 89, 97, 98, 119, 122, 123, 128
 - clearance and 23
 - elimination 73, 75, 93, 226
 - moderate 123
 - predictions 224, 226
- Henderson–Hasselbalch relationship 4
- human pharmacokinetics, predictions
 - clearance from human *in vitro* data 224, 225
 - commercial PBPK models 225
 - objectives of 212, 213
 - species scaling 225, 226
 - using *in vitro* data 222, 223
- human renal drug transporters 104
- human solid tumors 68, 69
 - blood supply, and 70
 - drug distribution into 70
- hydrogen bonding 2, 7, 47, 50, 65, 97, 117, 148, 161, 187, 237
 - functionality and 7, 8
- hydrophilic drugs 91
- hydrophobicity 2, 6, 115, 245

i

- IC₅₀ values 35, 163, 194, 201, 242, 243
- indocyanine green 22
- intravenous administration 21, 22
 - balance, expression by 21
 - clearance 22, 23
 - and half-life 23, 24
 - infusion 24, 25
 - with infusion rate doubled 25
 - plasma concentration profile 24, 25

- intrinsic lipophilicity (log *P*) 3–6, 47, 52, 95, 105
 - of compound 4, 5
 - principal contributions 6, 7
- itopride, as substrates for FMO3 132

k

- kidney anatomy, and function 103–105
- kinase inhibitors 90, 128
 - carboxylic-based Aurora kinase inhibitor 163
 - distribution into tumor 70

l

- lipid soluble substances 22
- Lipinski rules, defining boundaries of
 - absorption potential 47
- lipophilicity 2, 63, 92, 238, 239
 - in active transport of drugs 106, 107
 - alternative lipophilicity scales 10
 - in brain distribution 65
 - and CNS penetration, relationship between 66
 - computational systems to determine 10
 - correlates with increased metabolic liability and 46
 - defined 3
 - in determining affinity for receptors 93
 - and dihydropyridine calcium channel antagonists 98
 - and energy cost of desolvation 97
 - GFR, and unbound renal clearance, relationship 107
 - increasing, elimination half-life 93
 - and inhibition of CYP3A4 for azole, relationship 198
 - and limited range of partitioning 65
 - lipophilicity/clearance relationship 96
 - measures of 2–5
 - distribution coefficient (*D*) 4
 - partition coefficient *P* 3
 - and membrane permeability 9
 - and metabolic stability 100
 - Mglu5, CYP1A2, and relationship with 199
 - oral drugs, and lipophilic properties 100, 101
 - polarity in cycloalkyl motif lead to 125
 - and reabsorption by kidney 105, 106
 - relationship between unbound volume and 95
 - relationship for Cl_{i(u)} and 98
 - relationship with volume and 99
 - solvents and binding free energy 97

- structural features, and pharmacological activity 94, 95
- and total and unbound renal clearance in dog for 108
- unbound intrinsic clearance, and unbound renal clearance 95
- unbound renal clearance for neutral drugs, relationship with 106
- liposomes 11, 77
- lofentanil 37, 38

m

- MAO. *See* monoamine oxidases (MAO)
- membrane proteins 45
- membrane systems, to study drug behavior
- affinity (*k*) and capacity, of chlorphentermine for liposomes 11
 - for amine compounds, electrostatic interactions with 10
 - binding of chlorphentermine to 11
 - chloroquine, binding to phosphatidylserine 12
 - ionic interactions between basic drugs 10
 - membrane affinity 12
 - *in vitro* models 10
- membrane transfer 44–49
- access to target 62, 63
 - barriers to 49–51
 - passive process, for compounds 45
 - paracellular 45
 - transcellular 45
 - poor permeability, produced by 47
- metabolic clearance 91, 225, 226
- importance of lipophilicity in determining 91
- metabolic stability 89, 100, 109, 110, 118, 124, 226
- lipophilicity, key factor in 241
- metabolism-based design
- to increase oxidative clearance by 122, 123
 - of short-acting calcium-sensing receptor antagonists 123
- 7-methylsulfonyl-2,3,4,5,-tetrahydro-1H-3-benzazepines 203
- methyl transferases 147, 148
- metoprolol 50
- Michaelis–Menten kinetics 39
- microdialysis 65
- microsomal systems 241
- molecular size, in oral absorption 9
- monoamine oxidases (MAO) 133
- MAO-A mediated
 - metabolism of γ -amino butyric acid A receptor partial agonist 137

- mediated aspect of sertraline metabolism 137
 - oxidation of amines, by MAO-bound FAD 135
 - substrates and inhibitors, structures 133
- multidrug resistance proteins 69

n

- nitrogen-containing heterocycles 126, 127
- as aromatase inhibitors 197
 - capable of forming lone pair ligand interaction with 196
 - CYP inhibition by 195–199, 203
 - use in medicinal chemistry 198

o

- octanol 3
- limitations on use 5, 6
 - partitioning 106, 239
 - standardization 10
- Oie–Tozer allometry 215, 216
- opioid agonists 38
- oral absorption, of drug 42
- oral administration 26
- Cl_r values 27
 - deriving respective AUCs 27
 - disposition of drug after 26
 - first-pass effect 26, 27
 - oral clearance, equations for 27
- organic cation transporters 104
- hOAT1 and -3, transporters for basolateral uptake of 104
 - hOAT4, facilitate excretion of organic anions 104, 105
 - hOCT2, transport small organic cations 104
 - MRPs as primary active transporters 105
 - OATP4C1 mediate transport large compounds 105
 - OCTN1 and OCTN2, localized on apical membrane 104
- oxidation, of amines by MAO-bound FAD 135
- oxidative deamination
- FAD moiety is functional in 135
 - sertraline undergo 137
 - of structurally diverse amines 133
 - of triptan class of antimigraine drugs 136
 - by MAO-A 136
- oxidative metabolism 138
- aldehyde oxidase 126–130
 - and drug design 138
 - flavin-containing monooxygenases 130–133

- monoamine oxidases 133–137
- processes 126–137

p

- partition coefficient (log *P*) 2, 7, 63, 65, 76, 223, 239
- cyclosporine A 8, 9
- defined 3
- permeable drugs 13
- lower permeability compounds, accumulation into brain 67, 68
- P-glycoprotein (P-gp) 8, 49, 69, 243
- mediate cellular efflux 105
- pharmacodynamic models 34, 35
- plasma concentration
- and pharmacodynamic effect, relationship 34
- target site, occupancy of drugs 35
- pharmacogenomics 185, 186
- phosphatidylcholine (PC) 11
- phosphatidylethanolamine (PE) 11
- phosphatidylserine (PS) 11
- phospholipidosis 63
- phospholipids 11, 45
- physicochemistry
- importance of 236
- ionization 238 (*See also* p*K*_a values)
- lipophilicity 238, 239
- polar surface area 239
- properties, and relationship to key disposition processes 237
- solubility 237, 238
- physiologically based pharmacokinetic modeling 247, 248
- pirenzepine 37
- p*K*_a values 5, 72, 107, 145, 149, 238
- polar surface areas (PSA) 8, 63, 239
- polyethylene glycol (PEG) 42
- PPAR-γ agonist troglitazone, metabolized in human 150
- pregnane X receptor (PXR) 186
- agonist pharmacophore models 187
- receptor binding assays 187
- in regulation of drug metabolizing enzymes 186, 187
- prodrugs
- to aid membrane transfer 142, 144
- improving oral absorption 144
- oral bioavailability, strategies to improve 143
- tripartate prodrug concept 143
- to increase oral absorption 51–55
- acyclovir and valcyclovir, properties of 53
- dabigatran etexilate, and dabigatran 55

- fibrinogen receptor antagonist, and benzyl ester analogue 54
- pafenolol and celiprolol, and derivatives of talinolol 52
- physicochemical characteristics, of successful design 52
- propranolol 46, 50
- propylene glycol dipelargonate (PGDP) 10
- protein binding 244
- PSA. *See* polar surface areas (PSA)
- PXR. *See* pregnane X receptor (PXR)

r

- Raevsky H-bond scores 48
- from HYBOT95, correlation with Δlog *D* 47
- ramipril 109
- ramiprilat 109
- ranitidine, as substrates for FMO3 132
- reactive metabolite
- screening in drug discovery 171–173
- renal clearance 91
- and absorption, balancing 108, 109
- and drug design 109, 110
- effect of charge on 106
- plasma protein binding and 106–108
- renin inhibitor 46
- repeated doses 27–29
- average amount of drug 28
- dosing interval 29
- maximum and minimum amounts 28, 29
- ritonavir 44

s

- salbutamol 36
- salmeterol 36, 120
- single-species allometric scaling 215
- single-species scaling with fixed scaling factor 215
- slow offset compounds 35–38
- S_N2-type mechanism 145, 148, 149
- solubility 42
- high-throughput solubility screens 237, 238
- prediction 238
- role in gastrointestinal absorption 237
- testing 12
- thermodynamic 237
- sphingomyelin (SM) 11
- structural alerts/toxicophores 171
- structure–toxicity analyses 167–171
- sulfotransferases (SULTs)
- as enzymes catalyzing drug conjugation 144–147

- mechanisms apply to 145
 - metabolizing phenol- or catechol-containing drugs 49, 147
 - role of nucleophilicity 46
 - structure of minoxidil, compound metabolized by 153
 - x-ray crystal structure information 146, 147
- t**
- talinolol 50
 - tiotropium 37
 - tissue affinity, with basic drugs 22
 - topological polar surface area (TPSA) 8, 47, 239
 - toxicities 63, 160
 - and causes relating to stage of drug development 184
 - chemotype-dependent 161–164
 - clinical toxicities and side effects of CYP3A4 inducers 189
 - drugs withdrawn, due to hepatotoxicity 175–179
 - idiosyncratic drug toxicity 180–182
 - metabolism-induced 164–167
 - pharmacologic mechanism-based 160
 - prediction 183, 184
 - stratification of 183
 - toxicogenomics 184, 185
 - TPSA. *See* topological polar surface area (TPSA)
 - traditional allometry 213–215
 - transcellular diffusion 45
 - transport proteins 8, 242–244. *See also* organic cation transporters
 - active 243
 - of drugs in human brain 63
 - tumors, distribution of drugs into 68–70
- u**
- unbound drug 29–32
 - and drug action 29–32
 - antagonist ligands 30
 - dimensions, for transport 32
 - equilibrium between drug and receptor 29
 - equilibrium dissociation constant 30
 - equilibrium of drug receptor and unbound (free) drug 31
 - occupancy theory of drug response 30
 - receptor occupancy (RO) 31
 - receptor targets, accessed extracellularly 32
 - *in vitro* values 31, 32
 - factors governing, concentration of 38–40
 - model and barriers to equilibrium 32–34
 - pharmacodynamic/pharmacokinetic model 32
 - receptor occupancy based on PET scanning and 33
 - unbound (free) drug model, development of 30
 - unbound intrinsic clearance 95, 98, 125
 - of CYP3A4 substrates, and relationship with lipophilicity 124
 - reduced 100
 - uridine 5'-diphosphoglucuronosyltransferase 241
- v**
- volume of distribution (Vd) 21
 - and duration 70–77
 - effect of clearance and 24
 - of fluconazole 214
 - intravenous administration 21, 22
 - from *in vitro* data in human, prediction 222, 223
- w**
- warfarin 242
- x**
- xenobiotics 105
- z**
- Zwitterionic compounds 5

